PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$36.64 USD
+0.48 (1.33%)
Updated Sep 20, 2024 04:00 PM ET
3-Hold of 5 3
D Value B Growth D Momentum D VGM
Brokerage Reports
0 items in cart
PTC Therapeutics, Inc. [PTCT]
Reports for Purchase
Showing records 1 - 20 ( 147 total )
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology: Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Jan 16
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Core Franchise Intact with Extension of Conditional Approval for Translarna; Reiterate NEUTRAL and
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
3Q16 Beat for Translarna, but Regulatory Concerns Are an Overhang; Reiterate NEUTRAL and Lowering Price Target to $7
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Translarna Update - Round 2 with FDA as EMA Process Draws to a Close; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Catching Up with PTC Ahead of 4Q16 News Flow; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Translarna Still Growing as PTC Reports 2Q16; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
CHMP Translarna Discussions Lead to Plans for a New Trial; Reiterate NEUTRAL and Lowering PT to $10
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 25
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
NICE Finalizes Negotiations with PTC for Translarna; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 4
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Translarna with a Big Beat but Clinical and Regulatory Risk Remain; Reiterate NEUTRAL and Adjust our PT to $12
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
UK''s NICE Assesses all of the Data and Rules in Favor of Translarna Reimbursement; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
PTC Therapeutics Announces Plans to Reduce Costs for Managing Expenses in the US; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Translarna Review by Health Canada Pushed Back to Include Phase 3 ACT DMD Results; Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H